LY

Lyra Therapeutics IncNASDAQ LYRA Stock Report

Last reporting period 30 Sep, 2024

Updated 25 Nov, 2024

Last price

Market cap $B

0.018

Micro

Exchange

XNAS - Nasdaq

LYRA Stock Analysis

LY

Uncovered

Lyra Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-4/100

Low score

Market cap $B

0.018

Dividend yield

Shares outstanding

31.827 B

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-05-01. The firm's pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy. The firm's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.

View Section: Eyestock Rating